Oncolytics Biotech (ONCY) Projected to Post Earnings on Thursday

Oncolytics Biotech (NASDAQ:ONCY) is anticipated to release its Q2 2025 earnings data before the market opens on Thursday, August 7th. Analysts expect Oncolytics Biotech to post earnings of ($0.10) per share for the quarter.

Oncolytics Biotech (NASDAQ:ONCY) last issued its quarterly earnings results on Wednesday, May 14th. The company reported ($0.06) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.03. On average, analysts expect Oncolytics Biotech to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Oncolytics Biotech Trading Up 2.0%

Shares of NASDAQ:ONCY opened at $1.04 on Thursday. The company has a 50 day moving average of $0.78 and a 200-day moving average of $0.69. The firm has a market cap of $101.31 million, a P/E ratio of -3.59 and a beta of 1.07. Oncolytics Biotech has a twelve month low of $0.33 and a twelve month high of $1.53.

Wall Street Analyst Weigh In

ONCY has been the subject of a number of research analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $5.00 price target on shares of Oncolytics Biotech in a research note on Wednesday, May 21st. Jones Trading reaffirmed a “hold” rating on shares of Oncolytics Biotech in a research note on Friday, May 16th. One equities research analyst has rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat, Oncolytics Biotech has a consensus rating of “Moderate Buy” and a consensus target price of $4.33.

About Oncolytics Biotech

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.